Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 19

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 19
---
 number of securities or amount of proceeds as a condition to closing, and we may not sell all or any of these securities offered pursuant to this prospectus; as a result, we may receive significantly less in net proceeds. We cannot predict when or if the pre-funded warrants, the common warrants and the Placement Agent Warrants will be exercised, or if they will be exercised for cash. It is possible that the common warrants and the Placement Agent Warrants may expire and may never be exercised.

Each $0.10 increase (decrease)
in the assumed combined public offering price of $6.40 per share and accompanying common warrants would increase (decrease)
the net proceeds to us from this offering, after deducting the estimated placement agent fees and estimated offering expenses payable
by us, by $0.07 million, assuming that the number of shares and accompanying common warrants offered by us, as set forth
on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares and common warrants we
are offering. An increase (decrease) of 100,000 in the number of shares we are offering would increase (decrease) the net proceeds to
us from this offering, after deducting the estimated placement agent fees and estimated offering expenses payable by us, by $0.6
million, assuming the assumed combined public offering price stays the same.

We currently intend to use
the net proceeds from this offering to fund our research and development activities and for working capital and general corporate purposes.
Accordingly, we retain broad discretion over the use of the net proceeds from the sale of our shares and common warrants (or pre-funded
warrants and common warrants, if applicable), pursuant to this prospectus. The precise amount and timing of the application of such proceeds
will depend upon our liquidity needs and the availability and cost of other capital over which we have little or no control.

Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in a variety of capital preservation investments, short and intermediate term, interest-bearing, investment-grade instruments, U.S. government securities and highly rated corporate debt securities, although our investment policy may change following the date of this prospectus supplement. It is possible that, pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for us.

| 9 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our capital